Stress Markers and Post-COVID Insomnia: Investigating Copeptin and Melatonin Levels in Post-COVID-19

Insomnia is a prevalent symptom affecting 5.4% to 64% of individuals who have recovered from coronavirus disease 2019 (COVID-19). In this study, we aimed to elucidate the role of copeptin and melatonin in the pathogenesis of post-COVID-19 and insomnia in COVID-19 survivors. Thirty COVID-19-recovered patients and fifteen healthy controls were included in the study. Patients were categorized into two groups: Individuals with post-COVID insomnia having an insomnia severity index (ISI) score above 15 (n=10) and those without (n=20). Insomnia patients received either trazodone 50 mg or mirtazapine 15 mg as a sleep disturbance treatment once a day for three months. Serum copeptin and melatonin were evaluated. Melatonin and copeptin levels demonstrated a statistical significance between the study groups (p